Review decision – July 2021

Decision that the existing guidance remains relevant and an update is not needed

We would like to update you on the decision made regarding the review of the existing NICE technology appraisal guidance on ibrutinib for treating relapsed or refractory mantle cell lymphoma.

No substantial new evidence has been identified that would be likely to change the current recommendation in the guidance, therefore it is concluded that an update is not needed.

The guidance will remain unchanged, in its current form, unless or until NICE becomes aware of substantive information which would make it reconsider.

Review decision paper


This page was last updated: